Cargando…
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
BACKGROUND: We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry. METHODS: IBD medications that were...
Autores principales: | Agrawal, Manasi, Brenner, Erica J, Zhang, Xian, Colombel, Jean-Frederic, Kappelman, Michael D, Ungaro, Ryan C, Gearry, Richard B, Kalpan, Gilaad G, Kissous-Hunt, Michele, Lewis, James D, Ng, Siew C, Rahier, Jean-Francois, Reinisch, Walter, Ruemmele, Frank M, Steinwurz, Flavio, Underwood, Fox E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717203/ https://www.ncbi.nlm.nih.gov/pubmed/33232456 http://dx.doi.org/10.1093/ecco-jcc/jjaa243 |
Ejemplares similares
-
Sa502 THE FIRST AND SECOND WAVE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A TEMPORAL TREND ANALYSIS
por: Kaplan, Gilaad, et al.
Publicado: (2021) -
The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis
por: Kaplan, Gilaad G, et al.
Publicado: (2022) -
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
por: Brenner, Erica J., et al.
Publicado: (2020) -
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD
Patients in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2021) -
Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)